MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced its next-generation Operations Support System (ngOSS) , a new addition to the MAVscale platform.
The new solution brings together a powerful combination of Artificial Intelligence (AI), Analytics, Automation, and Orchestration, backed by Mavenir’s experience delivering telecom network solutions to allow Communication Service Providers (CSPs) to deploy ngOSS in their 4G networks today, while at the same time preparing to fully realize the potential of 5G capabilities through intelligent network operations.
By enhancing network performance, Mavenir’s ngOSS enables CSPs to improve the overall customer experience, lower operating expenses (OPEX), and reduce the risk of manual errors more prevalent in legacy OSS systems.
The end-to-end, cloud-native automation framework is built based on TM Forum’s Open Digital Architecture (ODA) and OpenAPIs that uses enhanced AI and Machine Learning (ML) models to deliver advanced network performance. Engineered with a microservices-based architecture, Mavenir's ngOSS solution simplifies large, legacy, monolithic systems into smaller, autonomous components that offer intelligence, insights, and network control. A more open, automated network is necessary to break legacy vendor lock-in while driving innovation for 5G use cases.
Mavenir is an OSS vendor with 4G/5G and mobile core/Radio Access Network (RAN) expertise, and in-depth understanding of orchestrating telecommunications workloads required for enabling advanced 5G capabilities, including network slicing, which translates directly into efficiencies for the CSPs.
“As CSPs advance toward automation, next-generation OSS will be a critical component to enable the network of the future,” said Kuntal Chowdhury, SVP and GM of AI and Analytics at Mavenir. “Using advanced AI and ML models to enhance network performance will help CSPs deliver superior customer experience, while scalable automation reduces manual tasks to lower maintenance costs and reduces the risk of human error. Mavenir’s ngOSS solution allows CSPs to break open the network and take advantage of Open APIs to increase agility and innovation, introduce new services, and monetize 5G with rapid service velocity.”
Key capabilities of Mavenir’s ngOSS include:
- Service Fulfillment and Orchestration – Service Order Management integrates with the Business Support System (BSS) layer using Open APIs to deliver dynamic order creation, support complex workflow creation, and offer complete visibility & management into service order execution. Service Orchestration provides a complete network automation solution, including Service Design, 5G Slice Management, and Network Service Orchestration.
- Data Management – Mavenir’s Provisioning and Activation function is radically different from the traditional provisioning offerings from legacy vendors. It elevates provisioning to a whole new level by offering Provisioning-as-a-Service on any cloud, from any vendor, on any domain approach. In addition, Mavenir’s Active Inventory collects, maintains, and exposes a federated real-time view of available network resources and services from across multiple cloud and vendor environments.
- Service Assurance and AI Operations (AIOps) – Mavenir Service Assurance and AIOps platform addresses CSP’s operational challenges by providing end-to-end visibility into the network, enabling an open network by integrating with any cloud, any vendor, and any technology domain, and performing critical AIOps functions, such as AI-driven predictive alarm correlation, ML-assisted Ticket Analysis, and auto Root Cause Analysis (RCA), resulting in increased productivity, shorter Mean Time To Repair (MTTR), and OPEX savings.
- Domain Controllers – Mavenir’s Non-Real-Time RAN Intelligent Controller (RIC) is a containerized application that uses advanced machine learning algorithms to optimize RAN performance and train ML models using long term RAN data for dynamic and adaptive policy and control. Mavenir’s Network Subnet Slice Management Function (NSSMF) is an open, cloud-native, and vendor-agnostic function that plays a crucial role in 5G slice management as it does the last-mile connections necessary to configure a slice.
Supporting documents:
Mavenir ngOSS webpage
Mavenir ngOSS solution brief
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
